Initial consumer insights on GLP-1 drugs from global market intelligence company Mintel shows that two camps are quickly forming: those open to utilising the drugs to manage weight and those who have no interest in the drugs but who want the benefits that come with the drugs
By activating these receptors, tirzepatide: Enhances insulin secretion in a glucose-dependent manner (reducing hypoglycaemia risk) Suppresses glucagon release, lowering hepatic glucose production Slows gastric emptying, promoting satiety Acts on central appetite centres in the hypothalamus to reduce food intake In clinical trials (SURMOUNT programme), tirzepatide produced significant weight loss (typically 1520% of body weight at the highest doses in carefully selected trial populations) alongside improvements in glycaemic control
Stopping GLP-1 therapy without an exit plan is analogous to stopping an antihypertensive because blood pressure normalized while on the drug
In August, semaglutide (Wegovy) received approval from the U.S
Establishing a baseline for comparison requires consistency
The bottom line is that coverage rules change frequently and vary widely between insurance companies
